http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017190309-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_04f60e2beb3c41a6a54cb70129e3db96 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-27 |
| filingDate | 2016-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8db03a044524fc2c911b10dc93ffe7d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_331f5208d590422982dcc3c269a4c441 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c53c5e51391d41f9b12e897ffbb9d372 |
| publicationDate | 2017-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2017190309-A |
| titleOfInvention | Rivastigmine transdermal absorption preparation |
| abstract | The present invention provides a transdermal absorption preparation containing a relatively large amount of rivastigmine and having an adhesive force that ensures safe administration over the entire administration period. The transdermally absorbable preparation of the present invention comprises a support layer and an adhesive layer, the adhesive layer comprising 10-50% rivastigmine or a pharmaceutically acceptable salt thereof, a self-crosslinking adhesive, And an acrylic polymer having a glass transition temperature of room temperature or higher as an essential component. The rivastigmine content is more preferably 20 to 45%. [Selection] Figure 1 |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7029244-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019026608-A |
| priorityDate | 2016-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.